EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study

Tiankuan Li, Xiaoyu Liu, Qungang Shan, Jingfeng Li, Wei Huang, Xiaoheng Hu

Frontiers in Oncology · 19.08.2026 · 16

DOI: 10.3389/fonc.2026.1890752 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Oncology, online erschienen am 19.08.2026. Verfasst von Tiankuan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Wuxi branch of Ruijin Hospital Shanghai, Wuxi, Jiangsu, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Irreversible electroporation (IRE) is a promising non-thermal ablative modality for advanced pancreatic cancer (APC). However, whether tumor location influences outcomes remain unclear due to distinct anatomical relationships between the pancreatic head/neck and body/tail. This study compared the safety, efficacy, and survival outcomes of IRE between patients with pancreatic head/neck and body/tail tumors.

Methods

We analyzed a real-world cohort of 63 consecutive patients with advanced pancreatic cancer (comprising primary, post-resection recurrent, and oligometastatic diseases) who underwent percutaneous CT-guided IRE between March 2018 and July 2024. Patients were stratified into the head/neck group (n=39) and the body/tail group (n=24). Baseline characteristics, procedural parameters, adverse events, overall survival (OS), event-free survival (EFS), and tumor marker changes (CA19-9/CEA) were compared.

Results

Median age was 66 years (head/neck) versus 61 years (body/tail) ( P = 0.468). The body/tail group had significantly higher body weight (median 56 vs. 47 kg, P = 0.021) and BMI (median 20.19 vs. 17.99 kg/m², P = 0.021). No significant differences were observed in IRE procedural parameters. Elevated serum amylase was the most common adverse event (61.5% vs. 58.3%, P = 1.000), and complication rates were comparable. Median OS from surgery was 8.7 versus 9.37 months ( P = 0.788), while OS from diagnosis was 22.80 versus 21.32 months ( P = 0.948). Median EFS was 6.00 versus 6.25 months ( P = 0.357). No significant differences were found in 1-month post-IRE CA19–9 or CEA ratio changes ( P = 0.783 and P = 0.295, respectively).

Conclusions

In this cohort of patients with relatively low BMI, percutaneous CT-guided IRE demonstrated comparable safety and efficacy between pancreatic head/neck and body/tail locations. Tumor location alone may not limit IRE feasibility; however, caution is needed when generalizing these findings to Western populations with higher BMI, and larger prospective studies are warranted.

Schlagwörter

Stichwörter der Autor:innen

advanced pancreatic cancerevent-free survivalirreversible electroporationoverall survivaltumor location

Autor:innen und Institutionen

  • Department of Interventional Radiology, Wuxi branch of Ruijin Hospital Shanghai, Wuxi, Jiangsu, China.
  • Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Zitieren

APA

Li, T., Liu, X., Shan, Q., Li, J., Huang, W., & Hu, X. (2026). Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1890752

Vancouver

Li T, Liu X, Shan Q, Li J, Huang W, Hu X. Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1890752

BibTeX
@article{Li2026,
  author = {Li, Tiankuan and Liu, Xiaoyu and Shan, Qungang and Li, Jingfeng and Huang, Wei and Hu, Xiaoheng},
  title = {Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1890752}
}
Kostenlos starten →